Psych Editorial
  • Home
  • Contact

Meet the Pfizer Executive Leadership Team: Ian C. Read

Meet the Pfizer Executive Leadership Team: Ian C. Read

Ian C. Read is Chairman of the Board and Chief Executive Officer of Pfizer, one of the world’s premier innovative biopharmaceutical companies, which brings therapies to patients that significantly improve their lives. These include medicines and vaccines along with many of the world’s best-known consumer healthcare products.

Previously, he served as Senior Vice President, Pfizer, and Group President of the Worldwide Biopharmaceutical Businesses, which he led from 2006 through December 2010. In that role, he oversaw five global business units — Primary Care, Specialty Care, Oncology, Established Products and Emerging Markets.

Ian began his career with Pfizer in 1978 as an operational auditor. He worked in Latin America through 1995, holding positions in a number of Pfizer’s largest, fastest-growing operations, including Chief Financial Officer, Pfizer Mexico, and Country Manager, Pfizer Brazil. In 1996, Ian was appointed President of Pfizer’s International Pharmaceuticals Group, with responsibility for Latin America and Canada. He became Executive Vice President, Europe, in 2000, was named a Corporate Vice President in 2001, and assumed responsibility for Canada, in addition to Europe, in 2002. Ian later became accountable for operations in both the Africa/Middle East region and Latin America as well.

Ian received his B.Sc. in chemical engineering from London University Imperial College in 1974. He earned his Chartered Accountants certification from the Institute of Chartered Accountants of England and Wales in 1978.

Ian serves on the Boards of PhRMA, Kimberly-Clark and the Partnership for New York City.

Source: Pfizer Press Releases – Meet Our Executives

Related Posts

Takeda Pharmaceuticals

Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh

Eli Lilly and Co., Executive Bios

Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero

News & Views

  • Now Accepting Content
  • Takeda and Lundbeck Announce FDA Approval of Brintellix™ (vortioxetine) for Treatment of Adults with Major Depressive Disorder
  • Introducing the New Kid on the Block to Treat Depression: “Brintellix”.
  • Meet the Executive Eli Lilly and Company Leadership Team: Fionnuala M. Walsh
  • Meet the Executive Eli Lilly and Company Leadership Team: Jacques Tapiero
Psych Editorial
Copyright © PhysicianEditorial.com
All Rights Reserved!